Determine the necessary mass, volume, or concentration for preparing a solution.
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 2 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Fasudil (HA-1077, AT-877), a potent and selective inhibitor ofRhokinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also acalcium channelblocker.
In vitro
Fasudil is a class of calcium antagonists. Fasudil produces a competitive inhibition of the Ca2+-induced contraction of the depolarized rabbit aorta. Fasudil is able to inhibit contractile responses to KCl, phenylephnne (PHE) and prostaglandin (PG) F2a. Fasudil also exhibits vasodilator actions by inhibition of 5-hydroxytryptamine, noradrenaline, histamine, angiotensin, and dopamine induced spiral strips contraction. Fasudil induces disorganization of actin stress fiber and cell migration inhibition. Fasudil inhibits hepatic stellate cells spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth, but does not induce apoptosis. Fasudil suppresses the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK.
In vivo
Intra-coronary injection of Fasudil to dogs (30 μg i.a.) produces an approximate 50% increase in CBF. Fasudil (0.01, 0.03, 0.1 and 0.3 mg/kg, bolus, i.v.) dose-dependently decreases MBP and increases HR, VBF, CBF, RBF, and FBF. A total dose of 1.0 ng/mL Fasudil increases cardiac output. The infusion of Fasudil i.v. produces a significant fall in MBP, left ventricular systolic pressure and total peripheral resistance with an increase in HR and cardiac output, but without significant changes in right atrial pressure, dP/dt or left ventricular minute work in dogs. Fasudil administration displays protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury. The oral administration of Fasudil (a dosage of 100 mg/kg/day) significantly reduces incidence and mean maximum clinical score of EAE in SJL/J mice immunized with PLP p139-151. Treatment of mice with Fasudil suppresses the proliferative response of splenocytes to the antigen. Oral administration of Fasudil decreases inflammation, demyelination, axonal loss and APP positivein spinal cord of Fasudil-treated mice.
Cell Data
cell lines:KB3-1, KBV-1, Hela, and Hs578T cells
Concentrations:
Incubation Time:
Powder Purity:≥99%
| Isómeros SMILES | C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl |
|---|---|
| WGK Alemania | 1 |
| RTECS | HM4033500 |
| CAS alternativo | 203911-27-7 |
| Peso molecular | 327.83 |
| Reaxy-Rn | 5466340 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5466340&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilidad | Solubility (25°C) In vitro Water: 48 mg/mL (198.57 mM); DMSO: Insoluble; Ethanol: Insoluble; |
|---|---|
| Índice de refracción | 1.62 |
| Punto de ebullición (°C) | 506.2° C |
| Punto de fusión (°C) | 222 °C |
| 1. Chen Wenyuanfeng, Qu Yuan, Liu Yining, Zhang Guorui, Sharhan Hasan M., Zhang Xinzhu, Zhang Kunwu, Cao Baocheng. (2024) Effects of fasudil on glial cell activation induced by tooth movement. Progress in Orthodontics, 25 (1): (1-13). [PMID:39034361] [10.1186/s40510-024-00518-2] |
| 2. Li Ying, Wang Lei, Guan Tianyue, Chen Yaru, Zhu Wenting, Liu Xiao, Li Yusa, Huang Hongyu, Dong Zibo, Zhang Honggang. (2025) Higenamine Hydrochloride Ameliorates Diabetic Cardiomyopathy Through RhoA/MEK/ERK Pathway. INFLAMMATION, [PMID:41469427] [10.1007/s10753-025-02403-4] |